Clinical trial · Observational
Faslodex Specific Clinical Experience Investigation
Faslodex Specific Clinical Experience Investigation for Long-term Use
NCT01501266CI-TRIAL-00022069completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in daily clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Faslodex
Primary outcomes (2)
- measure
- Incidence of adverse drug reactions.
- timeFrame
- 1 year
- measure
- Incidence of serious adverse events.
- timeFrame
- 1 Year
Secondary outcomes (3)
- measure
- Incidence of adverse drug reactions with injection site reaction, thromboembolic events and hepatic impairment
- timeFrame
- 1 year
- measure
- Progression-free survival
- timeFrame
- 6 month
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients treated with Faslodex for the first time due to postmenopausal breast cancer Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.